Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing ...
Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...
The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...
Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...
The following is a summary of “Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis,” published in the January 2025 issue of Psychiatry by Fountoulakis et al.
Cognitive-behavioral therapy lowered depression risk in teens, if their parents were not actively depressed. Risk for depression is two- to threefold higher in adolescents whose parents have ...